Deleterious variants in DNA damage response genes, mainly in lung cancer, are associated with a higher mutational burden (76), as observed in breast carcinomas with DNA damage repair gene variants (77) and in our tumor samples with BRCA1, BRCA2, and PALB2 variants. This evidence concerns the gene BRCA1 and neoplasm.